Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Arvinas now has 4 Phase 1 programs (LRRK2 for neurodegeneration, KRAS G12D for solid tumors, BCL6 for hematology, and an AR polyglutamine program for Kennedy's disease) and initiated the AR trial last month. Its prior lead ER degrader, vepdegestrant, produced positive pivotal data and an NDA is filed with the FDA, with a PDUFA date in early June 2026. The company has repositioned toward a Phase 1-focused pipeline; upcoming clinical readouts and the early-June PDUFA represent the key near-term catalysts that could move the stock modestly (roughly 1–3%).

Analysis

Repositioning into multiple first-in-human programs materially changes the company’s risk profile from one binary regulatory asset to a portfolio of early-stage binaries. Expect near-term volatility clusters around IND/GLP/CMC clears and first SAD/MAD readouts — each readout can move the equity >25% but also materially increase cash burn over the next 12–24 months as multiple cohorts progress in parallel.

Second-order winners include specialized CDMOs and analytical chemistry vendors that scale PROTAC-like or small-molecule degrader CMC work; constrained CDMO capacity for complex synthetic small molecules will bid up slot prices and negotiation power, compressing operating leverage for smaller biotechs lacking long-term manufacturing deals. Conversely, small biotech peers without diversified Phase 1 portfolios may see capital markets bifurcate — platform players command higher JV/licensing multiples while single-asset names face tougher financing spreads.

Key tail risks are classic: safety or tolerability signals in first-in-human cohorts, CMC bottlenecks that delay cohorts by quarters, and a need to raise non-dilutive capital quickly (or dilute existing holders). Timing matters: expect sentiment moves over days (post-event headlines), months (partnerships or early safety/PK), and 12–24 months (de-risking via multiple translational readouts) — any one adverse surprise can reset valuation multiples by 30–60%.

Contrarian angle: the market often underweights value from early-stage platform partnering — a single strategic deal can de-risk cash runway and re-rate much of the pipeline even absent clinical wins. That makes a volatility-focused approach attractive: capture asymmetric upside from partnership/readout-led re-ratings while actively managing headline-driven downside via defined-risk hedges.

Key Decisions for Investors

• Directional equity with hedge (ARVN): Buy a 1–2% notional position in ARVN equity and purchase 3–6 month protective puts ~10–15% OTM to cap headline risk. Timeframe: 3–12 months. Risk/Reward: downside limited to put premium (~3–6% of notional); upside if any program/partnership progress materializes could be +50–150%.
• Calendar/options spread (ARVN): Buy a 12‑month ATM LEAP call (e.g., Jan 2027) and finance by selling two sequential 2–3 month OTM calls (rolling if needed). Timeframe: 6–18 months. Risk/Reward: max loss = net debit (defined); path-dependent upside if one or more early clinical readouts or partner deals occur, targeting >2x return on a successful catalyst while collecting short-term premium to reduce cost basis.
• Volatility capture into noise (ARVN): If implied vol spikes on conference or press coverage, sell short-dated (30–45 day) call spreads or modest strangles sized to 0.5–1% notional to collect theta. Timeframe: days–weeks. Risk/Reward: limited upside = collected premium (target 2–6% of tranche); defined risk via spreads and stop-loss if stock gaps >20%, exploiting the tendency for post-event IV to mean-revert.
• Event-amplifier: partnership trigger scale-up: If a strategic collaboration or non-dilutive financing is announced, increase exposure to ARVN up to 3–4% notional and trim within 4–8 weeks. Timeframe: immediate after announcement. Risk/Reward: partnership can de-risk runway and re-rate multiple; recognize short-term profit-taking risk and set 20–30% trailing stop to lock gains.